The Gross Law Firm Reminds West Pharmaceutical Services, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 7, 2025 - WST

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of West Pharmaceutical Services, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements during the class period from February 16, 2023, to February 12, 2025 [1] Allegations - The complaint alleges that West Pharmaceutical Services claimed strong visibility into customer demand while actually experiencing significant destocking in its high-margin HVP portfolio [1] - The SmartDose device, positioned as a high-margin growth product, was found to be dilutive to profit margins due to operational inefficiencies [1] - Margin pressures from these issues raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with longstanding customers [1] - Positive statements made by the defendants regarding the company's business and prospects were deemed materially false or misleading [1] Class Action Details - Shareholders who purchased shares of WST during the specified class period are encouraged to register for the class action, with a deadline of July 7, 2025, to seek lead plaintiff status [2] - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2] Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3]